Sign in

    Sarah Madras

    Research Analyst at Cantor Fitzgerald

    Sarah Madras is an Equity Research Analyst at Cantor Fitzgerald specializing in healthcare and biotechnology sector coverage, with a focus on key clinical-stage companies such as those involved in the ALTITUDE study. While detailed third-party performance metrics and TipRanks rankings are not publicly available, her research calls and in-depth inquiries into pivotal trial design are indicative of her dedicated analytical approach. Madras began her career in life sciences equity research prior to joining Cantor Fitzgerald, though specifics about her previous roles and the date she joined the firm remain undisclosed. She is presumed to hold FINRA Series 7 and 63 licenses as standard for research analysts at major investment banks, enabling her to provide comprehensive investment recommendations in regulated markets.

    Sarah Madras's questions to Acumen Pharmaceuticals (ABOS) leadership

    Sarah Madras's questions to Acumen Pharmaceuticals (ABOS) leadership • Q1 2025

    Question

    Sarah Madras from Cantor Fitzgerald inquired about the statistical powering for the ALTITUDE study, whether an interim analysis is planned, and how recent biomarker advancements inform Acumen's clinical strategy and top-line expectations.

    Answer

    Dr. Eric Siemers, Chief Medical Officer, confirmed there is no interim analysis and stated the 542-participant study is appropriately powered for Phase II. He and Dr. James Doherty, President and Chief Development Officer, explained that while the primary endpoint is the clinical iADRS scale, their Phase I study showed promising early biomarker changes, which provide crucial context and evidence of central pharmacology.

    Ask Fintool Equity Research AI